Portal de Periódicos da CAPES

PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast

2017; Impact Journals LLC; Volume: 8; Issue: 13 Linguagem: Inglês

10.18632/oncotarget.15590

1949-2553

Qian Li, Xiangxiang Gao, Hua Huang, Shumin Lu, Yin Cai, Yu Hua, Yifei Liu, Jianguo Zhang,

Peptidase Inhibition and Analysis

// Li Qian 1, * , Xiangxiang Gao 2, * , Hua Huang 1 , Shumin Lu 3 , Yin Cai 3 , Yu Hua 3 , Yifei Liu 1 , Jianguo Zhang 1 1 Department of Clinical Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China 2 Department of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong Tumor Hospital, Nantong, Jiangsu, China 3 Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China * These authors contributed equally to this work Correspondence to: Jianguo Zhang, email: 13815212431@163.com Yifei Liu, email: ntdxliuyifei@sina.com Keywords: invasive ductal carcinoma, immunohistochemistry, PRSS3, prognosis Received: November 08, 2016 Accepted: January 27, 2017 Published: February 21, 2017 ABSTRACT Objective: Serine protease 3 (PRSS3) is an isoform of trypsinogen, and plays an important role in the development of many malignancies. The objective of this study was to determine PRSS3 mRNA and protein expression levels in invasive ductal carcinoma of the breast and normal surrounding tissue samples. Results: Both PRSS3 mRNA and protein levels were significantly higher in invasive ductal carcinoma of the breast tissues than in normal or benign tissues (all P < 0.05). High PRSS3 protein levels were associated with patients’ age, histological grade, Her-2 expression level, ki-67 expression, and the 5.0-year survival rate. These high protein levels are independent prognostic markers in invasive ductal carcinoma of the breast. Materials and Methods: We used real-time quantitative polymerase chain reactions ( N = 40) and tissue microarray immunohistochemistry analysis ( N = 286) to determine PRSS3 mRNA and protein expression, respectively. PRSS3 protein levels in invasive ductal carcinoma of the breast tissues were correlated with the clinical characteristics of patients with invasive ductal carcinoma of the breast and their 5.0-year survival rate. Conclusions: PRSS3 acts as an oncogene in invasive ductal carcinoma of the breast development and progression. This finding implies that detection of PRSS3 expression can be a useful prognosis marker and the targeting of PRSS3 can potentially represent a new strategy for invasive ductal carcinoma of the breast treatment.